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Abstract
Background: Sickle cell anemia is an inherited disorder of hemoglobin that leads to a variety of acute and chronic
complications. Abnormal cellular adhesion, mediated in part by selectins, has been implicated in the pathophysiology of the
vaso-occlusion seen in sickle cell anemia, and selectin inhibition was able to restore blood flow in a mouse model of sickle
cell disease.
Methods: We performed a Phase 1 study of the selectin inhibitor GMI 1070 in patients with sickle cell anemia. Fifteen
patients who were clinically stable received GMI 1070 in two infusions.
Results: The drug was well tolerated without significant adverse events. There was a modest increase in total peripheral
white blood cell count without clinical symptoms. Plasma concentrations were well-described by a two-compartment
model with an elimination T1/2 of 7.7 hours and CLr of 19.6 mL/hour/kg. Computer-assisted intravital microscopy showed
transient increases in red blood cell velocity in 3 of the 4 patients studied.
Conclusions: GMI 1070 was safe in stable patients with sickle cell anemia, and there was suggestion of increased blood flow
in a subset of patients. At some time points between 4 and 48 hours after treatment with GMI 1070, there were significant
decreases in biomarkers of endothelial activation (sE-selectin, sP-selectin, sICAM), leukocyte activation (MAC-1, LFA-1, PM
aggregates) and the coagulation cascade (tissue factor, thrombin-antithrombin complexes). Development of GMI 1070 for
the treatment of acute vaso-occlusive crisis is ongoing.
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Introduction
Sickle cell disease (SCD) results from a mutation in the b-globin
gene that leads to a substitution of valine for glutamic acid at
position 6 of the b globin chain. The most common genotypes
associated with disease are homozygous S (HbSS), and compound
heterozygous hemoglobin SC and S/b-thalassemia.[1,2] The
prevalence in the United States is between 70,000–100,000, but
is much greater in Africa and other parts of the world.
Complications are protean and affect every major organ system
including acute and chronic pain; ischemic and hemorrhagic
stroke; infections; acute chest syndrome and pulmonary hyper-
tension; congestive heart failure; azotemia, proteinuria, renal
concentrating defects, papillary necrosis, and priapism; osteomy-
elitis and avascular necrosis of the bone; and leg ulcers. Vascular
occlusion (or vaso-occlusive crisis – VOC) with ischemia-reperfu-
sion injury is thought to underlie most, if not all, of these
complications.
Based on early observations that deoxygenation or low pH
caused red blood cells from patients with HbSS to acquire a sickle
shape, it was thought that sickle cell vaso-occlusion resulted solely
from obstruction of small blood vessels with these rigid cells. It was
later recognized that sickle red cells (sRBC) from SCD patients
were aberrantly adhesive.[3–5] Multiple receptor-ligand adhesion
molecule interactions between sRBC and endothelial cells and
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sub-endothelial matrix underlie this enhanced adhesiveness.[6–12]
Furthermore, sRBC populations differ in their adhesiveness
(young RBCs or reticulocytes being more adherent than older,
more dense cells) and the degree of adhesiveness directly correlates
with clinical severity.[4] The model of VOC that emerged
involved initial adherence of sRBC reticulocytes to activated
endothelium with secondary adherence and capture of more
dense, rigid sRBC. Decreased adhesion molecule expression may
partially underlie the beneficial effect of hydroxyurea in patients
with SCD.[13] More recently, it has been suggested that platelets
and leukocytes (specifically neutrophils and monocytes) play a role
in acute and chronic morbidity as elucidated by in vitro and in
vivo studies.[14–18] Heterotypic adhesive events between red
cells, platelets, leukocytes, and endothelial cells, are emerging as a
model for sickle cell vaso-occlusion.
Several lines of clinical evidence suggest a role for leukocytes in
SCD pathogenesis.[19] Elevated leukocyte counts have been
associated with increased mortality[20] and acute chest syn-
drome.[21] The clinical benefit of hydroxyurea may be in part due
to a reduction of leukocytes in addition to other mechanisms
(increased fetal hemoglobin, decreased red cell adhesion molecule
expression, decreased leukocyte adhesion.[22–30] In transgenic
sickle cell mice, there is increased adherence of leukocytes to
endothelium compared with non-sickle control mice following
hypoxia or inflammatory stimuli.[14,31] This adherence, with
secondary capture of sickle red blood cells, is the initiating event of
VOC in this mouse model.
Turhan and colleagues demonstrated in a sickle mouse that
adherent leukocytes bound to post-capillary cremasteric ve-
nules.[14] Rolling and capture are mediated by selectins and
integrins, respectively. Leukocyte capture onto endothelium
stimulates signal transduction mediated conformational changes
in leukocyte integrins that further increase competence to bind
sickle red blood cells.
The selectins comprise a family of three members mediating
adhesion events between blood cells and the endothelium. L-
selectin is constitutively expressed on leukocytes and mediates
lymphocyte recruitment in lymph nodes and secondary tethers
between leukocytes and inactivated venules. Endothelial cells
express two selectins, P-selectin which is stored in Weibel-Palade
bodies and can be rapidly translocated to the cell surface upon
stimulation, and E-selectin whose expression is induced by
inflammatory cytokines such as TNF-a or IL-1b. Selectins mediate
leukocyte rolling along on the endothelium, allowing circulating
leukocytes to rapidly decelerate and come into close contact with
chemokines and induce firm adhesion.[32] Transgenic sickle mice
deficient in both P-and E- selectins exhibit severe defects in
leukocyte adhesion[33,34] and are protected from VOC.[14]
Studies of the individual function of single selectins in a mouse
model of SCD have revealed a key role for E-selectin, but not P-
selectin, in sending activating signals leading to the upregulation of
the b2 integrin, Mac-1, specifically at the leading edge of crawling
neutrophils in inflamed venules.[35]
Selectin ligands are composed of a trisaccharide domain
common to both sialyl Lea and sialyl Lex (sLea/x)[36]. GMI
1070 is a novel small molecule glycomimetic that was rationally
designed to contain both a more potent sLea/x mimetic and an
extended sulfated domain to accommodate the binding require-
ments of P-and L-selectins and confer drug-like properties to the
molecule.[37]
In mouse models containing human sickle hemoglobin, GMI
1070 prevented and reversed VOC when administered well after
initiation of the crisis in a clinically relevant treatment proto-
col.[38]. These data strongly suggest that targeting leukocyte
adhesion has therapeutic potential in sickle cell disease.
Based on these animal studies, we performed an open-label,
Phase 1 dose-ranging study of IV GMI 1070 in adults with stable
SCD. The primary objective was to evaluate the safety of two
intravenous (IV) doses of GMI 1070 in adults with sickle cell
disease (SCD). The secondary objectives were to evaluate the
pharmacokinetics (PK) of GMI 1070; measure the microvascular
blood flow before and after infusion with IV GMI 1070; and,
determine serial biomarkers of endothelial activation, inflamma-
tion, coagulation, and downstream selectin effect in the blood
before and after treatment with IV GMI 1070.
Methods
Ethics Statement
The Institutional Review Boards of the University of California,
Davis; Duke University; and Oakland Children’s Hospital
approved the study, and all patients gave signed, informed
consent. The study was conducted according to the principles of
Good Clinical Practice. The protocol for this trial and supporting
CONSORT checklist are available as supporting information: see
Checklist S1 and Protocol S1.
Eligible subjects were adults aged 18–50 years with an
established diagnosis of sickle cell disease/homozygous hemoglo-
bin S (SCD-SS) or sickle cell disease hemoglobin b0-thalassemia
(SCD-Sb0-thal). Disease activity had to be at the level of the
subject’s medical baseline, with no evidence of worsening over the
last 3 months (e.g. any acute complication of SCD that required
unscheduled medical attention or intervention) as determined by
the investigator.
This was an open-label, dose-ranging study of IV GMI 1070 in
adults with stable SCD. The initial dose level (A) was selected
based on preclinical data, and subsequent dose levels could be
adjusted in response to in-study data. Dose Level A, consisted of a
20 mg/kg loading dose of IV GMI 1070 (0 hours) followed by a
single 10 mg/kg dose of IV GMI 1070 1061 hours later. The
plan was to double the dose if target drug concentrations were not
achieved. Because target concentrations were achieved at Level A,
no dose escalation was done.
Sampling for PK, biomarkers, and IVM (to assess microvascular
blood flow) was performed immediately prior to the loading dose
and at specified intervals after the first and second doses of IV
GMI 1070.
Outcome Measures
Safety. The primary objective of the study was to evaluate the
safety of GMI 1070 in adults with SCD. Safety was assessed by
adverse event (AE) reporting, clinical laboratory test results,
physical examination, electrocardiogram (ECG), and concomitant
medication use. Subjects were to be followed for a total of 28 days
after dosing of study drug: a clinic visit at day 7 (6 2 days) and a
telephone follow-up at day 28 (6 3 days).
Pharmacokinetics. Pharmacokinetic parameters were as-
sessed using plasma concentrations and urinary excretions of
GMI 1070. Blood samples for PK were collected before dosing (on
the day of dosing) and at the following intervals after the first dose
of IV GMI 1070: 30 minutes, 2, 4, 8, 24, and 48 hours. Urine
sampling for PK was performed over a 6-hour period starting at
the beginning of the first dose. Plasma and urine concentrations of
GMI 1070 were measured using validated liquid chromatogra-
phy/tandem mass spectrometry (LC/MS/MS) assays with lower
limits of quantitation of 0.2 mg/mL and 0.5 mg/mL, respectively.
E-Selectin Inhibitor in Sickle Cell Anemia
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Pharmacodynamics. Computer-assisted intravital microsco-
py (CAIM) was performed at the UC Davis site as per previously
published methods[39–42] before dosing (on the day of dosing)
and at the following intervals following the first dose of IV GMI
1070: 30 minutes, 2, 4, 8, and 24 hours. Plasma sampling for
biomarkers of adhesion, inflammation, and downstream selectin
effect in the blood was performed before dosing and 4, 8, 24, and
48 hours after administration of the first dose of IV GMI 1070.
Analytes measured included: human sE-selectin, sICAM -1,
ICAM-3, sPECAM-1, sP-selectin and sVCAM-1 by multiplex
bead assay (eBioscience, San Diego, CA; D-dimer by ELISA,
tissue factor in plasma and thrombin-antithrombin complexes
(TAT), all by ELISA (Seikisui, Stamford, CT); and, surface
expression of monocyte b2 integrins MAC-1 & LFA-1; and
platelet-monocyte aggregates (PMA) by flow cytometry all
performed using modifications of previously described tech-
niques[17,43].
Briefly, samples were pre-treated with or without ADP, labeled
with or without anti-CD14-PE, and either anti-cd41a-APC or
anti-CD11b-APC, and fixed prior to shipment on ice to the lab.
Upon receipt, samples were centrifuged at 1000xg for 3–5 minutes
at room temperature to remove the fixative. Samples were then
washed once with 0.5ml Hepes Buffered Saline (HBS) and
transferred to FACS tubes. One aliquot of the cd14 labeled cells
was labeled on site with anti-CD11a-APC for 30 minutes at room
temperature. All samples were analyzed on the BD LSR Fortessa
Special Order Research Product flow cytometer (Becton Dick-
inson, San Jose, CA) with DIVA acquisition software and FlowJo
analysis software version 8.8.7 (Tree Star Inc. Ashland, OR).
Platelet-monocyte aggregates are defined as double positive events
(CD14+/CD41a+) and results are presented as percent of total
monocytes (CD14+). MAC-1 (CD11b) and LFA-1 (CD11a) results
are presented as mean fluorescence intensity (MFI) as compared to
the unlabeled cells.
Analysis Plan
The analysis populations included the following 3 populations:
1. Safety population – all subjects who received at least 1 dose of
investigational product (i.e., the loading dose) and had at least 1
post-baseline safety measurement (e.g., vital signs). The safety
population was used for summarizing baseline characteristics
and safety data.
2. Efficacy population – all subjects who received at least 1 dose of
investigational product (i.e., the loading dose) and had at least
subsequent 1 CAIM or biomarker measurement. The efficacy
population was used for the primary and secondary efficacy
analyses (CAIM and biomarkers of adhesion, inflammation,
coagulation, and downstream selectin effect).
3. Pharmacokinetic population – all subjects who completed the
study and had sufficient data for the PK analyses. The PK
population was used to summarize the plasma concentrations
of GMI 1070 over time, amount of GMI 1070 excreted in the
urine, and PK parameters.
Safety. Safety results were summarized descriptively and
presented in listings.
Pharmacokinetics. GMI 1070 plasma concentration, uri-
nary excretion, and PK parameters were summarized by
treatment group using descriptive statistics. Pharmacokinetic
parameters were estimated by fitting a 2-compartment IV infusion
model to each subject’s data. The primary PK parameters
estimated in fitting the model included total plasma clearance
(CL), intercompartmental clearance (CLD2), volume of the central
compartment (V1), and volume of the peripheral compartment
(V2). These primary parameters were used to calculate the
following secondary PK parameters: maximum observed drug
concentration (Cmax), time of maximum drug concentration
(Tmax), area under the plasma concentration-time curve to
infinity (AUC[inf]), apparent first-order distribution rate constant
(a), apparent first-order terminal elimination rate constant (b),
elimination half-life (tK), and volume of distribution at steady state
(Vss). Urine data were used in conjunction with the PK model to
estimate renal clearance for the collection period (CLr). The total
amount of drug excreted in the urine during the collection period
(Ue) was calculated from the urine concentration of drug (Cu) and
the volume of urine collected (Vu), and expressed as milligrams of
drug and percentage of administered dose recovered in the urine
(Fe). The AUC for the urine collection period was estimated from
the PK model, and CLr was calculated as CLr=Ue/AUC. All
modeling was done using WinNonlin Professional Version 5.2.
Pharmacodynamics. Serial red blood flow velocity from the
UC Davis site was calculated, tabulated, and presented in
graphical form. Other efficacy (pharmacodynamic) outcome
measures included biomarkers of endothelial activation, inflam-
mation, and downstream selectin effect in the blood measured at
4, 8, 24, and 48 hours after administration of the first dose of IV
GMI 1070.
Expression levels were compared against pre-treatment, and
stratified by HU use. Variables evaluated were the mean changes
in microvascular blood flow from baseline to each post-baseline
Table 1. Baseline Demographic Characteristics (Safety
Population).
GMI-1070
20 mg/kg + 10 mg/kg
Characteristic N=15
Statistic or Category n (%)
Age (years)
n 15
Mean 32.1
SD 10.62
Median 28.0
Min, max 19, 50
Gender – n (%)
Male 9 (60.0)
Female 6 (40.0)
Baseline weight (kg)
n 15
Mean 64.79
SD 9.90
Median 65.5
Min, max 48.3, 90.7
Genotype – n (%)
HbSS 13 (86.7)
HbSb0-thal 2 (13.3)
Hb = hemoglobin; max = maximum; min = minimum; SD = standard
deviation; thal = thalassemia.
doi:10.1371/journal.pone.0101301.t001
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assessment time point, and the changes in biomarkers from
baseline to each post-baseline time point.
The hypothesis of no difference between mean baseline value
and mean post-baseline value at each time point was assessed
using a mixed-effects model. The change from baseline in
microvascular blood flow and other biomarkers was modeled
longitudinally using a mixed-effects model, with subject as a
random effect and time, reader, interaction of time and reader,
and baseline value as fixed effects. For continuous variables with
repeated measures such as the biomarkers used in this trial, the
linear mixed model approach allows use of all the data available.
Results
A total of 15 patients were enrolled (Table 1 and Figure 1)
between May 28, 2009 (first subject enrolled) to July 6, 2010 (last
patient last visit) when adequate data was collected to allow for
planning of a Phase 2 study. All were African-American; nine were
males, and ages ranged from 19 to 50 years. Thirteen of the 15
had homozygous hemoglobin S disease. Five patients were on a
stable dose of hydroxyurea.
Figure 1. Enrollment Summary.
doi:10.1371/journal.pone.0101301.g001
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Safety
A total of 9 (60.0%) subjects reported 16 treatment-emergent
adverse events (TEAEs) during the study (Tables 2 and 3). The
most frequently reported were headache (4/15, 26.7%) and vaso-
occlusive crisis (VOC) (2/15, 13.3%). Three (20.0%) subjects had
TEAEs considered at least possibly related to study drug
(headache in 2 subjects and leukocytosis in 1 subject). Except for
grade 4 anemia (pre-existing as Grade 4, and worsening slightly
while on study) in one subject, all TEAEs were rated grade 1 or 2
in severity. One subject reported a TEAE involving skin. One
subject reported grade 1 pruritus of abdomen and back on Day 8,
which resolved with no treatment after 3 days.
No deaths, serious adverse events, or TEAEs leading to
discontinuation were reported during the study.
Eight (53.3%) subjects reported 10 TEAEs involving pain.
These included the headache and VOC (13 and 23 days after
infusion) already mentioned, and 1 (6.7%) subject each with
infusion site pain, arthralgia, and oropharyngeal pain. All of the
events were grade 1 in severity except for grade 2 headache in one
subject and grade 2 VOC in another. The headache began on
study Day 1 and was considered probably related to study drug. A
headache in another subject (grade 1, onset Day 2) was considered
possibly related. The remaining pain events were considered
unlikely related (7 subjects) or unrelated (oropharyngeal pain), with
onset days ranging from Day 1 to Day 24.
No notable trends in vital signs were observed during the study.
For each body system, the majority ($73.3%) of subjects had no
changes in physical examination findings, and those with changes
had findings that were not considered clinically significant.
Mean values for aspartate aminotransferase (AST) and lactate
dehydrogenase (LDH) were elevated at baseline and showed
decreases at subsequent time points, but they remained close to or
above the upper limit of reference range throughout the study. At
the Day 7 Visit, the mean (SD) changes in AST and LDH from
baseline were -13.9 (24.4) U/L and -98.9 (134.7) U/L, respec-
tively, and the mean (SD) observed values were 41.9 (14.6) U/L
and 629.9 (378.2) U/L. Mean values for total bilirubin were also
elevated at baseline (3.76 [3.08] mg/dL), and subsequent values
were generally similar to those at the Baseline Visit. The elevations
in AST, LDH, and total bilirubin were consistent with expected
abnormalities in individuals with SCD.
Hematocrit and hemoglobin values for the safety population
showed small mean increases from baseline at the Day 2 and 3
Visits. At the Day 3 Visit, the mean (SD) changes in hematocrit
and hemoglobin from baseline were 1.56 (1.80)% and 0.35 (0.62)
g/dL, respectively.
Moderate increases in neutrophil and total white blood cell
(WBC) counts were observed at the Day 2 Visit (24 hours), when
the mean (SD) values were 7.5 (5.5)6103/mm3 and 11.6
(6.6)6103/mm3, respectively (Figures 2–3). The corresponding
changes from baseline were significant: 3.2 (4.5)6103/mm3 (p-
value ,0.001) for neutrophil count and 2.3 (4.8)6103/mm3 (p-
value = 0.013) for WBC count. Mean values for neutrophil and
WBC counts returned to baseline values by Day 7. This pattern of
increase in neutrophil and WBC counts at the Day 2 Visit was
observed in the subjects who were not taking hydroxyurea during
the study. There was no significant increase in neutrophil counts at
24 hours in the patients taking hydroxyurea group (p = 0.2).
However, these data should be interpreted with caution given the
small sample size.
The high sensitivity C-reactive protein (hsCRP) level increased
from 4.3 (4.1) mg/L at the Baseline Visit to 9.0 (15.7) mg/L at the
Table 2. Overall Summary of Adverse Events (Safety Population).
GMI-1070
20 mg/kg + 10 mg/kg
N=15
Type of Event or Subjects with Type of Event n (%)
Treatment-emergent adverse events 16
Subjects with TEAEs1 9 (60.0)
Treatment-emergent SAEs 0
Subjects with treatment-emergent SAEs1 0 (0)
Treatment-related TEAEs 3
Subjects with treatment-related TEAEs1 3 (20.0)
Treatment-related SAEs 0
Subjects with treatment-related SAEs1 0 (0)
Subjects with TEAEs by severity2
Grade 1 5 (33.3)
Grade 2 3 (20.0)
Grade 3 0
Grade 4 1 (6.7)3
Subjects with TEAEs leading to discontinuation 0
Deaths 0
SAE = serious adverse event; TEAE = treatment-emergent adverse event.
1 Subjects who experienced 1 or more adverse event were counted once.
2 If a subject experienced more than 1 adverse event, the subject was counted only once for the worst (or maximum) severity.
3 Event was grade 4 anemia (hemoglobin 5.9 g/dL), which was not considered serious by the investigator.
doi:10.1371/journal.pone.0101301.t002
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Day 3 Visit, and then decreased to a level near baseline (4.2
[5.4] mg/L) at the Day 7 Visit. Two subjects had notable increases
in hsCRP during the study, with peak values of 50.4 and 40.7 mg/
L, respectively, at the Day 3 Visit. In both subjects, the increases
were associated with significant increases in WBC count, and in
one, with a pre-existing asymptomatic urinary tract infection
(Figure 4). Neither subject had symptoms of infection or
increased pain after treatment with GMI 1070.
Clinically significant laboratory test results (reported as adverse
events and requiring clinical follow-up) were reported in 3
subjects. One subject had a hemoglobin value of 5.9 g/dL (Day
7 Visit), decreased from a baseline of 6.0 g/dL. Another subject
had a WBC count of 28.06103/mm3 and 20.26103/mm3 (Day 2
and 3 Visits, respectively), and remained asymptomatic during this
time. Another subject had an elevated LDH (476 U/L at baseline);
decreased serum potassium (2.6 mEq/L at Day 3 Visit); increased
WBC count (18.8, 21.4, 23.1, 20.2, and 17.56103/mm3 at the
Baseline and Day 1 [post dose], 2, 3, and 7 Visits, respectively);
increased neutrophil count (12.8, 14.5, and 11.66103/mm3 at
Day 1 [post dose], 2, and 3, respectively); and several microscopic
urinalysis variables consistent with a pre-existing asymptomatic
urinary tract infection.
Pharmacokinetic Results
Fourteen (14) of the 15 subjects had sufficient data for PK
analysis. The PK of GMI 1070 in subjects with SCD was
consistent with a 2-compartment IV infusion model, and the
estimated clearances, volumes of distribution, T1/2 (7.7 hours) and
CLr (19.6 mL/hour/kg) were consistent with those observed
previously in healthy volunteers.[44–46] The model-predicted
plasma GMI 1070 concentrations for all 14 subjects in the PK
population showed excellent agreement with the observed
concentrations; this is illustrated with the mean data in Figure 5.
These results also demonstrated that the use of a loading dose
achieves immediate steady-state plasma concentrations of GMI
1070 in individuals with SCD and that the use of this dose level
(20 mg/kg loading dose) followed by a 10 mg/kg maintenance
dose achieves plasma concentrations expected to have activity in
this population.
Pharmacodynamic Results
At the UC Davis site, the mean observed RBC velocity showed
an increase over the baseline value at 30 minutes, 2 hours,
4 hours, 8 hours and 24 hours after dosing. The largest mean (SD)
increase in RBC velocity from baseline occurred 30 minutes post
dosing, with a value of 33.30 (13.52) pixels/sec (Figure 6). All four
subjects had detectable plasma levels of GMI 1070, consistent with
Table 3. Treatment-emergent Adverse Events by System Organ Class and Preferred Term (Safety Population).
GMI-1070
20 mg/kg + 10 mg/kg
System Organ Class N=15
Preferred Term n (%)
Any treatment-emergent adverse event 9 (60.0)
Nervous system disorders 4 (26.7)
Headache 4 (26.7)
Blood and lymphatic system disorders 2 (13.3)
Anemia 1 (6.7)
Leukocytosis 1 (6.7)
Congenital, familial, and genetic disorders 2 (13.3)
Sickle cell anemia with crisis1 2 (13.3)
Gastrointestinal disorders 1 (6.7)
Vomiting 1 (6.7)
General disorders and administration site conditions 1 (6.7)
Infusion site pain 1 (6.7)
Metabolism and nutrition disorders 1 (6.7)
Hypokalemia 1 (6.7)
Musculoskeletal and connective tissue disorders 1 (6.7)
Arthralgia 1 (6.7)
Respiratory, thoracic, and mediastinal disorders 1 (6.7)
Cough 1 (6.7)
Oropharyngeal pain 1 (6.7)
Skin and subcutaneous tissue disorders 1 (6.7)
Pruritus 1 (6.7)
Events are listed in descending order of frequency of preferred terms, with grouping by system organ class.
If a subject experienced more than 1 preferred term of adverse event, the subject was counted only once for that preferred term.
Urinary tract infection reported for one subject was not included because the event occurred on study Day -3.
1 New vaso-occlusive crisis.
doi:10.1371/journal.pone.0101301.t003
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plasma levels predicted by the PK model, during velocity
measurements. This trend toward an increase in RBC velocity
from baseline may indicate improved blood flow in small blood
vessels, but it did not reach statistical significance (all p-values .
0.05).
Statistically significant reduction of multiple biomarkers of
adhesion, activation, and coagulation was observed after treatment
with GMI 1070. Soluble adhesion markers were reduced after
8 hrs (soluble E-selectin), and after 4 and 8 hrs (soluble P-selectin;
ICAM-1). Tissue factor (TF) was reduced at 4 and 8 hrs (Table 4).
Thrombin-antithrombin complex (TAT) levels were reduced at all
time points (4 hr, 8 hr, 24 hr, 48 hr). The percentage of PMA was
reduced at 8 hrs. The expression of MAC-1 and LFA-1 was
reduced at all time points. When HU use was considered (HU–No;
HU–Yes), the levels of sEsel, sPsel, ICAM-1, TF, TAT, MAC-1,
and neutrophil counts were lower and more variable at baseline in
the HU-No group, significantly so for ICAM-1 (p = 0.048) and
MAC-1 (p = 0.001). After GMI 1070, significant reduction from
baseline was seen in both groups: in the HU-No group for ICAM-
1, TF, PMA, LFA-1, and in the HU-Yes group for sEsel, MAC-1,
TF, TAT. However, again due to the small sample size caution
should be exercised in interpreting these results.
Figure 2. Change in absolute neutrophil count from baseline.
doi:10.1371/journal.pone.0101301.g002
Figure 3. Change in total white blood cell count (WBC) from baseline.
doi:10.1371/journal.pone.0101301.g003
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Discussion
The primary objective of this study was to evaluate the safety of
two intravenous doses of GMI 1070 in clinically stable adults with
SCD. No serious adverse events were reported, and no subject
discontinued the study because of an adverse event. All adverse
events except one were grade 2 or less in severity. The single grade
4 event was anemia, which was considered to be non-serious by
the investigator and consistent with underlying sickle cell anemia.
Three subjects reported TEAEs considered possibly or probably
related to study drug, which included headache (2 subjects) and
leukocytosis (1 subject). Laboratory values showed no notable
trends of worsening over time. Overall no serious concerns were
identified in this study with regard to the safety of GMI 1070.
Moderate and significant mean increases in neutrophil (p-value
,0.001) and WBC (p-value = 0.013) counts were observed at the
Day 2 Visit (24 hours), followed by a return to values similar to
Figure 4. Change in total white blood cell count (WBC) in the two subjects with marked leukocytosis.
doi:10.1371/journal.pone.0101301.g004
Figure 5. Observed and model-predicted plasma concentrations of GMI-1070 after intravenous infusion.
doi:10.1371/journal.pone.0101301.g005
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baseline by Day 7. Thus, administration of GMI 1070 was
associated with neutrophilia and leukocytosis that were moderate
in intensity, temporally associated with plasma levels of the drug,
and reversible after elimination of the drug from the plasma.
These findings are consistent with the expected anti-adhesive effect
of selectin inhibition, and likely represent release of adherent
leukocytes from the vascular endothelium into the peripheral
circulation. Similar increases in neutrophil and WBC count were
not observed in the subgroup of subjects who took hydroxyurea
during the study, although small fluctuations in these counts were
seen in individuals.
The WBC and neutrophil results from this study suggests that
leukocyte adhesion can be inhibited at pharmacological levels in
patients with sickle cell disease, although whether this will be
enough to alleviate established vascular occlusion in patients
presenting in VOC remains to be seen. Leukocytosis could
theoretically have detrimental effect in patients with sickle cell
disease, such as increased incidence of acute chest syndrome or
infection. These potential adverse effects will have to be carefully
followed in further clinical studies.
A secondary study objective was to evaluate the PK of two IV
doses of GMI 1070 in adults with SCD. The plasma concentra-
tions were concordant with a 2-compartment IV infusion model,
and the estimates for clearances, volumes of distribution, tK, and
CLr were consistent with those observed previously in healthy
volunteers. The model-predicted plasma GMI 1070 concentra-
tions for all 14 subjects in the PK population showed excellent
agreement with the observed concentrations. The results support
the use of a 20 mg/kg loading dose followed by a 10 mg/kg dose
to rapidly reach and maintain plasma concentrations of GMI 1070
expected to be effective in individuals with SCD.
Another secondary objective was to evaluate microvascular
blood flow before and after administration of IV GMI 1070.
Previous work by our group has demonstrated that acute changes
in blood flow in response to various therapies are detectable by this
method.[39,47] Although subjects showed mean increases in RBC
velocity compared to baseline at 30 minutes and 2, 4, 8 and
24 hours post dosing, which may indicate improved blood flow,
the trend toward an increase in RBC velocity did not reach
statistical significance. However, the sample size (n = 4) may have
precluded finding significant differences. The timing was consis-
tent with observed WBC/ANC changes, suggesting pharmaco-
logic response of increased WBC and ANC may correspond with
improved microvascular flow.
The effects of GMI 1070 were evaluated on biomarkers known
to be elevated in sickle cell disease and mechanistically affected by
the target molecule, E-selectin. Markers of leukocyte activation
(MAC-1; LFA-1); platelet activation (soluble P-selectin; platelet-
monocyte aggregates or PMA); vascular inflammation (soluble E-
selectin; soluble ICAM-1); monocyte activation (PMA); and
coagulation system activation (tissue factor and thrombin-anti-
thrombin complexes) were serially measured. At some time point
between 4 and 48 hours after intravenous infusion of GMI 1070,
there were significant decreases in all these various markers
consistent with downstream inhibition of cellular activation and an
overall anti-inflammatory effect. In some individuals these changes
persisted at a time when drug plasma levels were below 10 mg/mL.
As the pathophysiology of VOC involves both leukocyte adhesion
and downstream inflammation,[15,16,48] these findings provide
further rationale for use of GMI 1070 in VOC.
When administered to adults with SCD at steady state, the pan-
selectin inhibitor GMI 1070 had safety and PK profiles similar to
those seen in healthy volunteers. This study provides mechanism-
based evidence of effect of GMI 1070 in this population and
supports further evaluation of the drug in the treatment of vaso-
occlusive crisis. A prospective randomized double-blinded Phase 2
trial of GMI 1070 in patients with SCD and VOC has been
conducted based on results of this Phase 1 study.
Figure 6. Mean change in RBC velocity as measured by computer-assisted intravital microscopy.
doi:10.1371/journal.pone.0101301.g006
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